Changes

m
no edit summary
Line 1: Line 1:  +
{{DISPLAYTITLE:Renal Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray}}
 +
 +
'''Table 1 - Recurrent Genomic Alterations in AML Detected by Chromosomal Microarray (Literature Review)'''.  This is a comprehensive list of CNAs and CN-LOH detectable by CMA testing with strong diagnostic, prognostic and treatment implications in AML.  Table derived from Xu et al., 2018 [PMID: 32434132] with permission from Cancer Genetics.
 
{| class="wikitable"
 
{| class="wikitable"
 
| colspan="8" |'''WHO Classification'''
 
| colspan="8" |'''WHO Classification'''
Line 6: Line 9:  
|'''Papillary RCC'''
 
|'''Papillary RCC'''
   −
'''Type 1'''  
+
'''Type 1'''
 
|'''Papillary RCC'''
 
|'''Papillary RCC'''
   Line 20: Line 23:  
|15-20%
 
|15-20%
 
|15-20%
 
|15-20%
| colspan="2" |1-5%
+
| colspan="2" | 1-5%
|5%
+
| 5%
|5%
+
| 5%
 
|-
 
|-
 
|'''Origin'''
 
|'''Origin'''
Line 41: Line 44:  
|1p- (10%) [2; R]
 
|1p- (10%) [2; R]
 
|
 
|
|1p- (25%) [2; R]
+
| 1p- (25%) [2; R]
 
| colspan="2" |1p- (30%) [3; R]
 
| colspan="2" |1p- (30%) [3; R]
 
|'''-1''' (90%) '''[1; D]<sup>c</sup>'''
 
|'''-1''' (90%) '''[1; D]<sup>c</sup>'''
Line 96: Line 99:  
|'''+7/+7,+7''' (84%) '''[1; D]<sup>c</sup>'''
 
|'''+7/+7,+7''' (84%) '''[1; D]<sup>c</sup>'''
 
|'''+7''' (25%) '''[1; D]'''
 
|'''+7''' (25%) '''[1; D]'''
| colspan="2" |+7 (30%) [3; R]
+
| colspan="2" | +7 (30%) [3; R]
 
|
 
|
 
|
 
|
Line 140: Line 143:  
|<nowiki>+12 (52%) [2; R]</nowiki>
 
|<nowiki>+12 (52%) [2; R]</nowiki>
 
|<nowiki>+12 (15%) [3; R]</nowiki>
 
|<nowiki>+12 (15%) [3; R]</nowiki>
| colspan="2" |+12 (35%) [3; R]
+
| colspan="2" | +12 (35%) [3; R]
 
|
 
|
 
|
 
|
Line 164: Line 167:  
|
 
|
 
|<nowiki>-15 (15%) [3; R]</nowiki>
 
|<nowiki>-15 (15%) [3; R]</nowiki>
| colspan="2" |-15 (15%) [3; R]
+
| colspan="2" | -15 (15%) [3; R]
 
|
 
|
 
|
 
|
Line 260: Line 263:  
| colspan="8" |'''Mutations (SNVs, Indels) [level of evidence; clinical significance]'''
 
| colspan="8" |'''Mutations (SNVs, Indels) [level of evidence; clinical significance]'''
 
|-
 
|-
|Mutated
+
| Mutated
    
in >20%
 
in >20%
Line 270: Line 273:  
|
 
|
 
|-
 
|-
|Mutated
+
| Mutated
    
in 10-20%
 
in 10-20%